ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK) fusions, particularly echinoderm microtubule-associated protein-like 4 (EML4)-ALK variants, are key oncogenic drivers in non-small cell lung cancer.
• Mutations within the ALK kinase domain can confer resistance to ALK tyrosine kinase inhibitors (TKIs), necessitating a deeper understanding of their impact on kinase activity and drug sensitivity.

Purpose of the Study:

• To investigate the functional consequences of the F1174S mutation in EML4-ALK variants 1, 3a, and 3b.
• To assess the impact of the F1174S mutation on EML4-ALK kinase activity, oncogenicity, and sensitivity to ALK TKIs.

Main Methods:

• Construction and characterization of wildtype and F1174S mutant EML4-ALK variants 1, 3a, and 3b using mammalian expression plasmids.
• Functional assays including immunoblotting, neurite outgrowth, focus formation, and protein stability assays.
• Comparative drug sensitivity analysis to ALK TKIs between wildtype and F1174S mutant EML4-ALK fusions.

Main Results:

• EML4-ALK variant 1 with the F1174S mutation exhibited impaired kinase activity and reduced oncogenicity, contrasting with previously reported activating ALK mutations.
• In contrast to other F1174 mutations (C/L/V), the F1174S mutation sensitized EML4-ALK variants 3a and 3b to the TKI crizotinib.
• The study characterized the effects of various F1174 kinase domain mutations within the EML4-ALK fusion context.

Conclusions:

• The F1174S mutation in EML4-ALK variant 1 is unlikely to be a potent oncogenic driver, suggesting other mechanisms may be involved in resistance.
• Findings underscore the complexity of selecting appropriate therapies for patients with ALK-driven cancers harboring resistance mutations.
• The differential sensitivity of EML4-ALK variants to crizotinib based on F1174 mutation status highlights the need for personalized treatment strategies.